Gentamicin

Introduction Overview

Generic Name

gentamicin

Brand Name

Garamycin, Cidomycin

Dosage Form

injectable solution, intravenous solution

Drug Class

Aminoglycosides

Pharmacokinetics

Absorption:
Gentamicin is not absorbed orally due to its polar nature and is therefore administered parenterally, mainly by intravenous (IV) or intramuscular (IM) routes. After IM administration, gentamicin is rapidly and almost completely absorbed, achieving therapeutic plasma concentrations typically within 30–90 minutes. The absorption rate is dependent on blood flow and muscle mass at the injection site. IV administration ensures 100% bioavailability and allows for precise control of plasma drug levels, which is critical in treating severe infections. Due to its poor lipid solubility and high polarity, gentamicin does not penetrate the gastrointestinal tract, necessitating its parenteral route of delivery.

Distribution:
Gentamicin displays a relatively small volume of distribution (approx. 0.2-0.3 L/kg), reflecting its confinement predominantly to extracellular fluids. It penetrates well into body fluids such as urine, pleural fluid, ascites, and pericardial fluid but has limited penetration into cerebrospinal fluid unless the meninges are inflamed. The drug crosses the placenta and is found in fetal tissues in low concentrations. Protein binding is minimal (ranging 10-30%), which means most of the drug remains free and active in plasma. Distribution is influenced by factors such as hydration status, edema, and body weight, which may necessitate dosage adjustments, especially in critical care settings.

Metabolism:
Gentamicin is not metabolized in the body; it remains unchanged. This lack of biotransformation simplifies pharmacokinetic monitoring but underscores the critical importance of renal excretion for drug clearance. Absence of hepatic metabolism reduces the risk of hepatic drug-drug interactions. Consequently, any impairment in renal function directly correlates with altered gentamicin elimination and potential toxicity.

Elimination:
Gentamicin is primarily excreted unchanged by the kidneys via glomerular filtration, with an elimination half-life of approximately 2 to 3 hours in patients with normal renal function. In neonates, the half-life is prolonged up to 4–5 hours, and it can be further lengthened in patients with renal impairment due to decreased clearance. The majority of an administered dose (around 90%) is eliminated within 24 hours in individuals with normal renal function. Because of this renal dependence, dosage adjustments based on creatinine clearance and serum drug monitoring are essential to prevent nephrotoxicity and ototoxicity. Hemodialysis can remove gentamicin, whereas peritoneal dialysis is less efficient.

Dosage Forms

Available Dosage Forms:
Gentamicin is available primarily as injectable formulations designed for intravenous and intramuscular administration. Specific formulations include:
- Injectable solution: 10 mg/mL and 40 mg/mL concentrates
- Intravenous solution with 0.9% sodium chloride: 60 mg/50 mL, 80 mg/50 mL, 80 mg/100 mL, 100 mg/50 mL, 100 mg/100 mL, and 120 mg/100 mL

Dosages for Adults and Adolescents:
The typical dosing regimen for gentamicin varies based on the severity and type of infection, renal function, and patient weight. Conventional dosing generally involves 3 to 5 mg/kg/day divided into 2 to 3 equally spaced doses administered intravenously or intramuscularly. Extended-interval dosing (once daily) is also used to optimize efficacy and reduce toxicity. Treatment duration commonly ranges from 7 to 10 days but can be extended in severe infections. Dose adjustment is critical in patients with renal impairment using serum drug concentrations and creatinine clearance.

Specific Patient Populations:
- Neonates and pediatrics: Dose adjustment is required due to immature renal function and altered volume of distribution. Neonatal half-life can extend up to 5 hours; dosing intervals are often prolonged.
- Elderly: Renal function monitoring is vital as reduced clearance increases toxicity risks.
- Renal impairment: Dose or dosing frequency adjustments based on estimated glomerular filtration rate and therapeutic drug monitoring.
- Pregnant women: Not recommended due to potential fetal harm.
- Patients with neuromuscular disorders (e.g., myasthenia gravis) require caution due to potential exacerbation.

Mechanism Of Action

Gentamicin's primary mechanism of action involves inhibition of bacterial protein synthesis through binding to specific sites on the 30S ribosomal subunit. This binding causes misreading of mRNA during translation, leading to incorporation of incorrect amino acids into nascent polypeptide chains, resulting in defective or nonfunctional proteins. This ultimately leads to bactericidal activity across a broad spectrum of aerobic gram-negative bacilli and some gram-positive organisms.

At the molecular level, gentamicin interacts irreversibly with the A site of the 16S rRNA within the 30S ribosomal subunit, destabilizing the initiation complex and causing premature termination of protein synthesis. This disrupts the bacterial cell’s ability to maintain vital functions including cell wall synthesis, enzyme production, and membrane integrity.

Clinically, this mechanism leads to rapid bacterial killing, which is concentration-dependent, meaning higher drug concentrations improve bactericidal effects. Gentamicin exhibits synergistic effects when combined with beta-lactam antibiotics, which disrupt bacterial cell wall permeability, facilitating gentamicin entry.

Comparatively, other aminoglycosides (e.g., tobramycin, amikacin) share similar mechanisms but differ slightly in spectrum and toxicity profiles. Research also indicates that gentamicin can induce reactive oxygen species formation contributing to bacterial cell damage, although the primary mechanism remains ribosomal inhibition. Additionally, resistance mechanisms such as enzymatic modification of gentamicin molecules can impair binding, limiting efficacy.

Pharmacological Actions

Bactericidal antibiotic activity against a broad range of aerobic gram-negative bacteria, including Pseudomonas aeruginosa, Escherichia coli, Klebsiella species, and Proteus species.
Exhibits synergistic antibacterial effects with beta-lactam antibiotics and vancomycin against certain gram-positive bacteria like Enterococci and Staphylococci.
Disrupts bacterial protein synthesis by binding irreversibly to the 30S ribosomal subunit, causing production of aberrant proteins.
Concentration-dependent killing with a post-antibiotic effect, allowing for extended dosing intervals in certain clinical scenarios.
Limited activity against anaerobic bacteria due to oxygen-dependent transport into bacterial cells.
Minimal metabolism and primarily renal excretion, resulting in predictable pharmacokinetics in patients with normal kidney function.
Potential nephrotoxic and ototoxic effects due to accumulation in renal tubular cells and inner ear hair cells, necessitating therapeutic drug monitoring.
Does not cross the blood-brain barrier significantly; used primarily for systemic infections outside the central nervous system.
Pregnancy category D due to potential teratogenicity and risk to fetal hearing and kidney function.
Inhibition of neuromuscular transmission leading to potential exacerbation of neuromuscular disorders such as myasthenia gravis.
Displays post-antibiotic effect, inhibiting bacterial regrowth even after plasma levels fall below the MIC.
Resistance mechanisms include enzymatic modification by aminoglycoside-modifying enzymes, altered ribosomal binding sites, and reduced cellular uptake.

Therapeutic Or Clinical Uses

Treatment of serious bacterial infections caused by susceptible gram-negative organisms, including septicemia and bacteremia.
Management of complicated urinary tract infections, especially those caused by Pseudomonas aeruginosa and multi-drug resistant strains.
Treatment of lower respiratory tract infections such as hospital-acquired pneumonia caused by susceptible pathogens.
Adjunct therapy for serious enterococcal and staphylococcal infections, often combined with penicillins or vancomycin.
Use in bone and joint infections (osteomyelitis and septic arthritis) in combination with other agents.
Infection prophylaxis in certain surgical procedures, particularly to prevent gram-negative bacterial infections.
Treatment of intra-abdominal infections, such as peritonitis, caused by susceptible aerobic bacteria.
Use in cystic fibrosis patients to control Pseudomonas aeruginosa infections via systemic administration.
Topical and ophthalmic gentamicin formulations (not detailed here) for superficial skin and eye infections.
Alternative therapy for infections resistant to other aminoglycosides or beta-lactams, especially in multidrug-resistant bacterial infections.
Management of external and middle ear infections (otitis externa and otitis media) in specialized formulations.
Treatment of endocarditis caused by gram-negative organisms as part of combination therapy.
Use in neonates for treatment of sepsis and meningitis caused by susceptible bacteria with adjusted dosing.
Management of complicated intra-thoracic infections including empyema.

Side Or Adverse Effects

Nephrotoxicity manifesting as acute tubular necrosis leading to impaired renal function, especially with prolonged use or high doses.
Ototoxicity including vestibular and cochlear damage resulting in hearing loss, tinnitus, dizziness, or balance disturbances.
Neurotoxicity presenting with peripheral neuropathy, neuromuscular blockade, muscle weakness, and rare cases of apnea due to respiratory muscle paralysis.
Hypersensitivity reactions such as rash, itching, hives, and rare anaphylaxis.
Injection site reactions including pain, erythema, and inflammation.
Gastrointestinal disturbances including nausea, vomiting, and loss of appetite.
Electrolyte imbalances potentially due to renal tubular dysfunction leading to hypokalemia, hypomagnesemia, and hypocalcemia.
Headache and mood changes including confusion and dizziness.
Potential exacerbation of myasthenia gravis symptoms due to neuromuscular blockade.
Rare occurrences of superinfection or secondary infections including Clostridium difficile-associated diarrhea.
Elevated serum creatinine and blood urea nitrogen as markers of renal impairment.
Fever, mouth ulcers, and inflammatory gum changes associated with systemic reactions.
Flushing or skin sensitivity reactions, especially in sulfite-allergic individuals due to preservatives in injectable formulations.
Rare seizures (convulsions) and neuromuscular excitability.
Local tissue toxicity if extravasation occurs during intravenous administration.

Precautions

Monitor renal function regularly due to risk of nephrotoxicity; adjust dosage accordingly especially in patients with pre-existing renal impairment.
Perform baseline and periodic audiometric testing to detect early signs of ototoxicity during prolonged therapy.
Use caution and appropriate dosing adjustments in neonates, elderly patients, and those with dehydration or electrolyte imbalances.
Avoid concomitant use with other nephrotoxic or ototoxic drugs such as loop diuretics and amphotericin B.
Discontinue gentamicin immediately if signs of hearing loss, tinnitus, or vestibular dysfunction occur.
Carefully evaluate neuromuscular function in patients with myasthenia gravis or other neuromuscular disorders prior to and during therapy.
Avoid intrathecal or epidural administration; gentamicin is not approved for CNS infections due to poor penetration.
Use effective contraception during therapy as gentamicin is contraindicated during pregnancy due to teratogenic risks.
Do not use gentamicin if the solution contains discoloration or particles; inspect vial prior to administration.
Ensure adequate hydration to reduce risk of nephrotoxicity and facilitate renal clearance.
Avoid mixing gentamicin with other medications in the same IV line or syringe due to incompatibility.
Discontinue therapy if signs of severe allergic reactions develop and provide appropriate medical intervention.
Administer using proper aseptic techniques and single-use disposable equipment to prevent infection transmission.
Maintain careful therapeutic drug monitoring to optimize dosing and minimize toxicity, particularly with extended or high-dose regimens.
Advise patients to report symptoms of neurotoxicity, including muscle twitching, weakness, or breathing difficulties immediately.

Warnings

Gentamicin has significant potential to cause nephrotoxicity, especially in patients with pre-existing kidney disease or when used concomitantly with other nephrotoxic agents.
Ototoxicity, which can be irreversible, may occur, particularly with prolonged treatment or high serum concentrations; symptoms include hearing loss, tinnitus, and balance disorders.
Use with caution in patients undergoing neuromuscular blocking therapy or with neuromuscular disorders due to risk of enhanced neuromuscular blockade.
Gentamicin is contraindicated during pregnancy because of risk of fetal harm including ototoxicity and nephrotoxicity.
Renal toxicity risk is increased in the elderly, neonates, and dehydrated patients; close monitoring and dosage adjustments are imperative.
Administration errors such as intra-arterial injection can cause severe tissue damage.
Use of gentamicin in combination with other antibiotics requires monitoring for additive toxicity.
Risk of electrolyte imbalances secondary to renal tubular dysfunction necessitates periodic serum electrolyte monitoring.
Discontinue gentamicin immediately if signs of severe allergic or anaphylactic reactions occur.
Patients requiring surgery must inform surgeons about gentamicin use due to potential interactions with anesthetic and neuromuscular blocking agents.
Avoid improper storage as degradation and contamination increase risk of adverse events.
Do not use in patients with known hypersensitivity to gentamicin or related aminoglycosides to prevent hypersensitivity reactions.
Overdose can cause severe respiratory depression requiring emergency intervention.
Potential for superinfection with prolonged use requires vigilance and possible modification of therapy.
Special caution is advised in sulfite-allergic patients due to preservatives in some injectable gentamicin products.

Contraindication

Known hypersensitivity or allergy to gentamicin or other aminoglycoside antibiotics such as amikacin, tobramycin, kanamycin, neomycin, paromomycin, or streptomycin.
Pregnancy, due to documented risk of fetal ototoxicity and nephrotoxicity.
Pre-existing severe renal impairment without close monitoring and dosage adjustments.
Use in patients with a history of hypersensitivity reactions to gentamicin formulations or any component of the injectable solutions.
Patients with myasthenia gravis or neuromuscular disorders should generally avoid gentamicin due to risk of exacerbation unless no suitable alternatives exist.
Patients with known sulfite allergy should avoid certain preservative-containing gentamicin injections.
Not indicated for viral infections or non-bacterial etiologies.
Contraindicated for oral administration due to lack of systemic absorption and potential local toxicity.
Avoid concomitant administration with other neurotoxic or nephrotoxic agents without stringent monitoring.
Contraindicated in patients with previous severe neurotoxicity attributed to gentamicin.

Drug Interactions

Concurrent use with other nephrotoxic drugs (e.g., amphotericin B, cisplatin, cephalosporins, vancomycin, loop diuretics like furosemide) increases risk of renal impairment.
Co-administration with neuromuscular blocking agents (e.g., succinylcholine, pancuronium) may potentiate respiratory muscle paralysis.
Use with loop diuretics can enhance ototoxicity risk due to additive inner ear toxicity.
Concurrent use with other aminoglycosides or antibiotics with similar toxicities can increase adverse event risk.
Drugs affecting renal function (e.g., nonsteroidal anti-inflammatory drugs, ACE inhibitors) may reduce gentamicin clearance and increase toxicity.
Potential additive neurotoxicity with drugs such as polymyxins and bacitracin.
Concurrent administration with potassium-depleting diuretics may exacerbate electrolyte disturbances.
Interactions with anticholinesterase agents (used in myasthenia gravis) may worsen neuromuscular blockade.
Avoid mixing gentamicin with other drugs in the same syringe or IV line to prevent chemical incompatibility.
Co-administration with warfarin may increase bleeding risk indirectly by altering gut flora, though evidence is limited.
Increased risk of oto- and nephrotoxicity when combined with cisplatin chemotherapy.
Some antivirals and immunosuppressants (e.g., cyclosporine) may amplify nephrotoxic effects when used concurrently.
Concurrent use with muscle relaxants during surgery may require careful respiratory monitoring.
Use caution when combined with sulfonamides and beta-lactams due to potential for antagonistic or synergistic effects in susceptibility patterns.
Potential interaction with herbal supplements that affect kidney function or electrolyte balance, e.g., licorice or ginseng.

Preparations Of The Drug

Injectable solution: Gentamicin sulfate available in concentrations of 10 mg/mL and 40 mg/mL for IM or IV injection.
Intravenous infusion solutions: Various premixed solutions in 0.9% sodium chloride including 60 mg/50 mL, 80 mg/50 mL, 80 mg/100 mL, 100 mg/50 mL, 100 mg/100 mL, and 120 mg/100 mL for IV infusion administration.
Single-dose vials designed for sterile preparation and administration in hospital or clinical settings.
Multi-dose vials containing preservatives may be used for repeated dosing but require strict aseptic technique.
Specialty formulations combined with sodium chloride or dextrose to optimize stability and compatibility for IV infusion.
Sterile powder forms are available for reconstitution but less commonly used clinically.
No oral formulations due to negligible gastrointestinal absorption.
Topical and ophthalmic preparations exist but are outside the scope of systemic gentamicin usage.
Packaging usually includes appropriate labeling about storage conditions (room temperature, protected from moisture and light).
Designed for single-use and disposal following local regulations to prevent needle-stick injuries and contamination.
May contain sulfites as preservatives that require caution in sensitive patients.
Preparation and dispensing require adherence to compounding guidelines and proper dilution practices to maintain drug stability and efficacy.